A specialty pharmaceutical company focused on developing prodrug versions of existing medicines to improve safety, dosing, and abuse-deterrence, primarily targeting central nervous system disorders. Its pipeline and commercial strategy have centered on ADHD and related neurological treatments, inclu...
1 member of Congress has disclosed 2 trades in KemPharmaceuticals Incorporated (KMPH), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-08-23 | JAMES B. RENACCI | sell | $15K – $50K |
| 2015-06-13 | JAMES B. RENACCI | buy | $15K – $50K |